Talquetamab plus teclistamab achieved a high response rate of 79% in patients with drug-resistant, true extramedullary myeloma. Median progression-free survival was 15.4 months and overall survival at 12 months was 74%. Adverse events were consistent with known profiles, leading to discontinuation in 6% of patients.
Study
|
Multicenter, nonrandomized, open-label, phase 2 study [RedirecTT-1 NCT04586426] |
| Relapsed/refractory, true extramedullary myeloma |
| Talquetamab (0.8 mg/kg) + Teclistamab (3.0 mg/kg) every 2 wks (n=90)
|
Efficacy
|
ORR: 79% (CR in 54%) |
| mDoR: 13.8 mos |
| mPFS: 15.4 mos |
| 12-mo PFS: 61% |
| 12-mo OS: 74%
|
Safety
|
Grade >=3 AEs: hematologic events (76%), infections (31%) |
| Discontinuation: 6% due to nonfatal AEs |
| Deaths: 11%, 5 treatment-related
|
N Engl J Med 2026;394:51-61
Kumar S, Mateos MV, Ye JC Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
http://doi.org/10.1056/NEJMoa2514752
Reviewed by Ulas D. Bayraktar, MD on Jan 21, 2026
